New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 14, 2014
08:58 EDTACORAcorda Therapeutics delays start of Phase 3 study of dalfampridine-QD to 2H
Acorda Therapeutics announced that the initiation of its Phase 3 study of dalfampridine-QD in people with post-stroke walking deficits will begin in the second half of 2014; previously the company had projected study initiation in the second quarter of 2014. The developer of the once-daily, or QD, formulation has informed the company of an alcohol dose dumping finding in vitro and the company will need to perform a short clinical study to determine whether this also exists in vivo. The clinical study will be conducted in healthy volunteers and is expected to be completed in the third quarter of 2014, Acorda said.
News For ACOR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 27, 2015
09:49 EDTACORAcorda Therapeutics gets another IPR challenge from Hayman group
The Coalition For Affordable Drugs, a group linked to Hayman Capital's Kyle Bass, has requested an Inter Partes Review of Claims 1–3, 5–8, and 10–41 of U.S. Patent No. 8,007,826 held by Acorda Therapeutics (ACOR), according to a USPTO filing. The patents relate to the company's multiple sclerosis treatment. BACKGROUND: On February 10, the same coalition requested an Inter Partes Review of claims 1–8 of “the ’685 patent” held by Acorda. On January 7, Reuters reported that Bass planned to take "around 15 pharmaceutical companies with a combined market capitalization of $450B" into an Inter Partes Review for extending patents in questionable ways, citing a presentation made by Bass in Oslo. PRICE ACTION: Shares of Acorda are down 2.6% to $34.62 in early trading.
February 24, 2015
07:33 EDTACORMaxim to hold a discussion
Subscribe for More Information
February 20, 2015
13:38 EDTACORLeerink specialty pharma analyst holds analyst/industry conference call
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use